Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Extract of Gelidium elegans inhibits lipid differentiation, accumulation, and synthesis in vitro and in vivo. It has also anti-obesity effect by inhibiting weight gain and decreasing body fat. In a preliminary study of obese adults aged 20 years or older, the extracts of Gelidium elegans showed a tendency to decrease in body fat and visceral fat, and to increase lean body mass. Based on these results, we tried to confirm the effect of body weight and body fat reduction of Gelidium elegans extract in overweight and obese people.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Test group | Experimental | taken 3 tablets of Gelidium elegans extract (1000 mg/day) once a day for 12 weeks |
|
| Control group | Placebo Comparator | taken 3 tablets of placebo once a day for 12 weeks |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Exract of Gelidium elegans | Dietary Supplement | Exract of Gelidium elegans will be given to the test group. |
|
| Measure | Description | Time Frame |
|---|---|---|
| change in body fat mass by DEXA after 12-week treatment | 12 week | |
| change in visceral, subcutaneous, total fat area and ratio of visceral and subcutaneous fat area will be combined to report by Fat CT after 12-week treatment | 12 week |
| Measure | Description | Time Frame |
|---|---|---|
| change in body weight and body fat mass will be combined to report by Bio-impedance | 6 week | |
| change in body weight and body fat mass will be combined to report by Bio-impedance | 12 week | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Family Medicine, Severance Hospital, College of Medicine, Yonsei University | Seoul | South Korea |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo | Dietary Supplement | Placebo supplement will be given to the test group. |
|
| change in waist circumference |
| 6 week |
| change in waist circumference | 12 week |
| change in hip circumference | 6 week |
| change in hip circumference | 12 week |
| change in ratio of waist and hip circumference | 6 week |
| change in ratio of waist and hip circumference | 12 week |
| body mass index | 6 week |
| body mass index | 12 week |
| change in lean body mass by DEXA | 6 week |
| change in lean body mass by DEXA | 12 week |
| change in laboratory test result of total cholesterol, HDL, LDL and triglyceride will be combined to report as lipid profile | 6 week |
| change in laboratory test result of total cholesterol, HDL, LDL and triglyceride will be combined to report as lipid profile | 12 week |
| change in laboratory test result of CRP | 6 week |
| change in laboratory test result of CRP | 12 week |
| change in laboratory test result of fasting insulin | 6 week |
| change in laboratory test result of fasting insulin | 12 week |
| change in HOMA-IR | 6 week |
| change in HOMA-IR | 12 week |
| change in HOMA-beta | 6 week |
| change in HOMA-beta | 12 week |
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |